Pharmaceuticals, Biotechnology and Life Sciences
Faron Pharmaceuticals (Faron), the clinical stage biopharmaceutical company, has recruited the first patient in the Japanese Phase III pivotal clinical trial for the…
Esperite`s business unit The Cell Factory in collaboration with Women`s and Children`s Health Department of the University of Padua and the Padua University Hospital are developing therapies for inflammatory bowel disease (IBD) using extracellular vesicles (EVs).
Transgene, a company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases, announced the launch and terms of a share capital increase with shareholders’ preferential subscription rights for a total gross amount of circa €48 million, issue premium included (the “Rights Issue”).
Genomic Vision, DNA molecular combing specialist that develops tests for the diagnostics market and tools for the life sciences research market, has presented, at the Annual Meeting of the American Society of Human Genetics, the initial results of the pilot study undertaken with Quest Diagnostics that aims to identify a biomarker to improve genetic counseling for Spinal Muscular Atrophy (SMA) in the African-American population.
The company on Thursday said the Placing Shares are being offered by an accelerated bookbuild. Zeus Capital and N+1 Singer will be acting as joint bookrunners in connection with the Bookbuild, Quantum Pharma has said.
FDA approves Roche’s cancer immunotherapy TECENTRIQ (atezolizumab) for people with a specific type of metastatic lung cancer.
GW Pharmaceuticals plc has announced leaving AIM and canceling trading in London, to continue trading only on NASDAQ.
Advanced Oncotherapy , the developer of proton therapy systems for cancer treatment, has announced on Tuesday that planning permission for the Harley Street site was granted.
KEOPSYS Group holding company, acquired for € 5 million, 93.8% of the capital of EURODYNE, which holds 1,184,513 QUANTEL shares and 1,928,579 voting rights, representing 14.6% of the capital and 21.3% of the voting rights of QUANTEL.
Quantum Pharma names new CEO and makes other board changes
@qp_group